Cartesian Therapeutics Shares Are Trading Higher After Leerink Partners Initiated Coverage on the Stock With an Outperform Rating and Announced a $39 Price Target
在Leerink Partners以跑贏大盤的評級啓動了對該股的報道並宣佈了39美元的目標股價之後,Cartesian Therapeutics的股價走高
Cartesian Therapeutics Shares Are Trading Higher After Leerink Partners Initiated Coverage on the Stock With an Outperform Rating and Announced a $39 Price Target
在Leerink Partners以跑贏大盤的評級啓動了對該股的報道並宣佈了39美元的目標股價之後,Cartesian Therapeutics的股價走高
使用瀏覽器的分享功能,分享給你的好友吧